Q2 2026 Holdings
Filed 2026-08-14 | 58 holdings | $1.1B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Liquidia Corporation(LQDA) | COM NEW | 53635D202 | $195.1M | 2,447,500 | 17.7% |
| Eton Pharmaceuticals Inc(ETON) | COM | 29772L108 | $103.5M | 2,860,000 | 9.4% |
| Harrow Inc(HROW) | COM | 415858109 | $101.9M | 2,400,000 | 9.2% |
| Disc Medicine Inc(IRON) | COM | 254604101 | $62.5M | 855,000 | 5.7% |
| Urogen Pharma LTD(URGN) | COM | M96088105 | $53.0M | 1,439,996 | 4.8% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $51.8M | 390,000 | 4.7% |
| Meiragtx Hldgs PLC(MGTX) | COM | G59665102 | $48.0M | 3,550,000 | 4.3% |
| Sol-Gel Technologies LTD(SLGL) | SHS NEW | M8694L137 | $37.1M | 500,000 | 3.4% |
| Rezolute Inc(RZLT) | COM NEW | 76200L309 | $32.8M | 6,300,000 | 3.0% |
| TG Therapeutics Inc(TGTX) | COM | 88322Q108 | $29.4M | 535,000 | 2.7% |
| Immix Biopharma Inc(IMMX) | COM | 45258H106 | $24.2M | 2,345,000 | 2.2% |
| Crescent Biopharma Inc.(CBIO) | COM | G2545C104 | $23.7M | 1,319,351 | 2.2% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $22.9M | 700,000 | 2.1% |
| Alpha Cognition Inc(ACOG) | COM NEW | 02074J501 | $20.9M | 2,895,467 | 1.9% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $20.3M | 500,000 | 1.8% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $18.7M | 100,000 | 1.7% |
| Monte Rosa Therapeutics Inc(GLUE) | COM | 61225M102 | $18.0M | 745,000 | 1.6% |
| Alumis Inc(ALMS) | COM | 022307102 | $15.5M | 550,000 | 1.4% |
| Codexis Inc(CDXS) | COM | 192005106 | $15.3M | 6,785,000 | 1.4% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $15.3M | 1,384,993 | 1.4% |
| Xoma Royalty Corporation(XOMA) | COM NEW | 98419J206 | $14.4M | 338,374 | 1.3% |
| MBX Biosciences Inc(MBX) | COM | 55287L101 | $14.4M | 260,000 | 1.3% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $13.6M | 122,500 | 1.2% |
| Editas Medicine Inc(EDIT) | COM | 28106W103 | $12.5M | 3,861,930 | 1.1% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $12.3M | 100,000 | 1.1% |
| Cabaletta BIO Inc(CABA) | COM | 12674W109 | $12.0M | 3,863,800 | 1.1% |
| Q32 BIO Inc(QTTB) | COM | 746964105 | $11.9M | 931,000 | 1.1% |
| Annexon Inc(ANNX) | COM | 03589W102 | $9.8M | 1,714,451 | 0.9% |
| Verastem Inc(VSTM) | COM NEW | 92337C203 | $6.9M | 1,800,000 | 0.6% |
| Zentalis Pharmaceuticals Inc(ZNTL) | COM | 98943L107 | $6.9M | 1,412,656 | 0.6% |
| Relmada Therapeutics Inc(RLMD) | COM | 75955J402 | $6.5M | 935,000 | 0.6% |
| Ocular Therapeutix Inc(OCUL) | COM | 67576A100 | $5.9M | 600,000 | 0.5% |
| Trevi Therapeutics Inc(TRVI) | COM | 89532M101 | $5.8M | 310,000 | 0.5% |
| Bridgebio Oncology Therapeut(BBOT) | COM NEW | 107924102 | $5.3M | 700,000 | 0.5% |
| Lyell Immunopharma Inc(LYEL) | COM NEW | 55083R203 | $4.8M | 344,025 | 0.4% |
| Opus Genetics Inc(IRD) | COM | 67577R102 | $4.6M | 1,125,000 | 0.4% |
| 4D Molecular Therapeutics in(FDMT) | COM | 35104E100 | $4.4M | 334,437 | 0.4% |
| Intellia Therapeutics Inc(NTLA) | COM | 45826J105 | $4.2M | 250,000 | 0.4% |
| Voyager Therapeutics Inc(VYGR) | COM | 92915B106 | $4.1M | 1,185,000 | 0.4% |
| Biodesix Inc(BDSX) | COM | 09075X207 | $4.1M | 180,000 | 0.4% |
| Rocket Pharmaceuticals Inc(RCKT) | COM | 77313F106 | $3.4M | 1,000,000 | 0.3% |
| Jade Biosciences Inc(JBIO) | COM NEW | 008064206 | $3.2M | 145,000 | 0.3% |
| Sanuwave Health Inc(SNWV) | COM | 80303D305 | $3.1M | 306,140 | 0.3% |
| Fortress Biotech Inc(FBIO) | COM NEW | 34960Q307 | $2.7M | 890,000 | 0.2% |
| Journey MED Corp(DERM) | COM | 48115J109 | $2.5M | 350,000 | 0.2% |
| Phathom Pharmaceuticals Inc(PHAT) | COM | 71722W107 | $2.0M | 185,589 | 0.2% |
| Inhibrx Biosciences Inc(INBX) | COM | 45720N103 | $1.9M | 20,291 | 0.2% |
| Enanta Pharmaceuticals Inc(ENTA) | COM | 29251M106 | $1.8M | 125,000 | 0.2% |
| Hemab Therapeutics Hldgs Inc(COAG) | COM SHS | 423494103 | $1.8M | 47,652 | 0.2% |
| First Tracks Biotherapeutics(TRAX) | ORD SHS | 337185102 | $1.3M | 65,000 | 0.1% |